Literature DB >> 4629252

Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies.

A B Bjornson, J G Michael.   

Abstract

The opsonic, agglutinative, and mouse protective capacities of anti-Pseudomonas antibodies in immune and normal human immunoglobulin G (IgG) preparations were investigated. Opsonic activities of the immune IgG preparations correlated well with their protective activities. Antibodies present in normal IgG showed a substantial agglutinative activity but were poorly protective. Anti-Pseudomonas antibodies of both normal and immune IgG preparations were directed against the same serotype antigen as demonstrated by absorption experiments. Immune anti-Pseudomonas IgG antibodies fixed complement very efficiently as demonstrated by opsonophagocytic and hemolytic tests. Natural anti-Pseudomonas IgG antibodies fixed complement very poorly although they promoted phagocytic killing of bacteria only in the presence of heat-labile serum factors. It was concluded that, although agglutination can be used for qualitative measurement of antibacterial antibodies, it fails to measure their functional capacities.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4629252      PMCID: PMC422439          DOI: 10.1128/iai.5.5.775-782.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Measurement of the protective effect of antibody in burned and unburned patients' sera for Pseudomonas aeruginosa infected mice.

Authors:  C D GRABER; D CUMMINGS; E H VOGEL; W T TUMBUSCH
Journal:  Tex Rep Biol Med       Date:  1961

2.  The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis.

Authors:  P V LIU; Y ABE; J L BATES
Journal:  J Infect Dis       Date:  1961 Mar-Apr       Impact factor: 5.226

3.  Immunity to Pseudomonas pyocyanea in man.

Authors:  J E FOX; E J LOWBURY
Journal:  J Pathol Bacteriol       Date:  1953-04

4.  Passive immunization against experimental pseudomonas infection: correlation of protection to verder and evans "o" serotypes.

Authors:  J A Bass; J C McCoy
Journal:  Infect Immun       Date:  1971-01       Impact factor: 3.441

5.  C'-1 fixation by human isoagglutinins: fixation of C'-1 by gamma-G and gamma-M but not by gamma-A antibody.

Authors:  T Ishizaka; K Ishizaka; T Borsos; H Rapp
Journal:  J Immunol       Date:  1966-11       Impact factor: 5.422

6.  Antiserum and antibiotic in the prophylaxis of burns against Pseudomonas aeruginosa.

Authors:  R J Jones; D M Jackson; E J Lowbury
Journal:  Br J Plast Surg       Date:  1966-01

7.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

8.  Evaluation of gamma globulin for prophylaxis against burn sepsis.

Authors:  H H Stone; C D Graber; J D Martin; L Kolb
Journal:  Surgery       Date:  1965-11       Impact factor: 3.982

9.  Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. I. Interaction between immunoglobulins, heat-labile serum factors, and phagocytic cells in the killing of bacteria.

Authors:  A B Bjornson; J G Michael
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

10.  The antigenic and molecular alterations of C3 in the fluid phase during an immune reaction in normal human serum. Demonstration of a new conversion product, C3x.

Authors:  R E Spitzer; A E Stitzel; V L Pauling; N C Davis; C D West
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

View more
  10 in total

1.  Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

Authors:  J E Pennington; G J Small; M E Lostrom; G B Pier
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

2.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

3.  Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.

Authors:  M R Moody; R W Kessel; V M Young; P Fiset
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

4.  Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia.

Authors:  L Harvath; B R Andersen
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

5.  Protective effects of S-sulfonated human gamma globulin against experimental infections in mice.

Authors:  H Tomioka; Y Iwamura; Y Suzuki; S Ohtomo; Y Hashimoto
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

6.  Influence of anti-slime glycolipoprotein serum on the interaction between Pseudomonas aeruginosa and macrophages.

Authors:  P F Bartell; A Krikszens
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

7.  Synergistic effect on mortality in mice with murine cytomegalovirus and Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans infections.

Authors:  J R Hamilton; J C Overall; L A Glasgow
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

8.  Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.

Authors:  J F Pittet; M A Matthay; G Pier; M Grady; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

9.  Degradation of host defenses against respiratory tract infection by Klebsiella pneumoniae in aged mice.

Authors:  Y Yokota; Y Wakai; Y Mine; S Goto; M Nishida; S Kuwahara
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

10.  Reduced resistance to Pseudomonas septicaemia in diabetic mice.

Authors:  Y Kitahara; T Ishibashi; Y Harada; M Takamoto; K Tanaka
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.